|1.||Woodgett, James R: 8 articles (05/2010 - 05/2006)|
|2.||Jope, Richard S: 8 articles (01/2007 - 04/2002)|
|3.||Luo, Jia: 7 articles (09/2009 - 07/2004)|
|4.||Chen, Gang: 7 articles (09/2009 - 07/2004)|
|5.||Thiemermann, Christoph: 7 articles (09/2008 - 09/2005)|
|6.||Shakoori, Abbas: 6 articles (12/2009 - 09/2005)|
|7.||Minamoto, Toshinari: 6 articles (12/2009 - 09/2005)|
|8.||Billadeau, Daniel D: 6 articles (04/2009 - 03/2005)|
|9.||Miura, Tetsuji: 5 articles (10/2010 - 11/2007)|
|10.||Li, Yan: 5 articles (09/2010 - 07/2005)|
12/01/2009 - "In conclusion, with the use of our protocols, EPO showed better protective effects than IPost against reperfusion injury through higher phosphorylation of GSK-3beta."
08/01/2011 - "Inhibition of glycogen synthase kinase 3 beta ameliorates liver ischemia reperfusion injury by way of an interleukin-10-mediated immune regulatory mechanism."
06/01/2010 - "Mitochondria and GSK-3beta in cardioprotection against ischemia/reperfusion injury."
07/01/2009 - "GSK-3beta phosphorylation is a step to which multiple protective signaling pathways converge, and thus GSK-3beta phosphorylation is crucial in cardioprotection of a variety of interventions against ischemia/reperfusion injury. "
07/01/2007 - "Inhibition of GSK-3beta by Li or IMI improves tolerance to ischemia/reperfusion injury in hypertrophied myocardium. "
07/15/2008 - "These findings identify GSK-3beta signaling as a key regulator of radiation-induced damage in hippocampal neurons and suggest that GSK-3beta inhibitors may have a therapeutic role in protecting both pediatric and adult cancer patients and may help to improve quality of life in cancer survivors."
01/01/2009 - "Our study also demonstrated significant correlation between GSK3beta nuclear localization and tumor grade (p = 0.02), suggesting its association with tumor progression. "
01/01/2007 - "Moreover, recent studies in other human malignancies have implicated GSK-3beta as a regulator of cancer cell proliferation, survival and chemoresistance through distinct mechanisms. "
10/01/2014 - "Glycogen synthase kinase 3 beta (Gsk3b) acts as a negative modulator in endothelial cells through the Wnt/β-catenin/PI3K/AKT/Gsk3b axis in cancer-induced angiogenesis. "
06/12/2014 - "Glycogen synthase kinase 3 beta (GSK3β) is highly inactivated in epithelial cancers and is known to inhibit tumor migration and invasion. "
|3.||Brain Injuries (Brain Injury)
08/01/2006 - "The present study suggests that the Akt/GSK3beta pathway might be involved in neuronal survival in acute brain injury after SAH."
05/01/2007 - "We conclude that reduction in oxidative stress by SOD1 overexpression may attenuate acute brain injury after SAH via activation of Akt/GSK3beta survival signaling."
08/01/2006 - "Akt/GSK3beta survival signaling is involved in acute brain injury after subarachnoid hemorrhage in rats."
09/01/2006 - "Our findings suggest that estradiol plays a potent protective role against brain injury and that phosphorylation of Akt and GSK3beta by estradiol mediated these protective effects."
08/01/2006 - "LY294002 reduced Akt and GSK3beta phosphorylation and increased brain injury after SAH. "
|4.||Schizophrenia (Dementia Praecox)
08/01/2004 - "We report a significant reduction in CSF GSK-3beta protein levels in six schizophrenia patients compared to seventeen healthy subjects. "
03/01/2008 - "This study examined whether Par-4, beta-arrestin1, AKT1 and GSK-3beta are involved in the pathophysiology of schizophrenia. "
12/01/2004 - "The present study lends further support to the finding of low GSK-3beta levels in schizophrenia and extends this observation by suggesting that the decrease in GSK-3beta may be due to reduced protein synthesis possibly due to altered transcriptional drive of the GSK-3beta gene."
08/01/2004 - "In this study we aimed to find whether the reduction in brain GSK-3beta is reflected in CSF of schizophrenia patients. "
01/01/2004 - "Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3beta gene polymorphisms with schizophrenia."
|5.||Bipolar Disorder (Mania)
04/01/2002 - "These results demonstrate that several drugs therapeutic for bipolar disorder can provide neuroprotection by inhibiting the pro-apoptotic effects of GSK-3beta, providing new evidence that dysregulation of GSK-3beta may contribute to the pathophysiology of bipolar disorder."
07/04/2007 - "This study presents the first demonstration of the efficacy of a GSK-3beta inhibitor in this mouse model of mania. "
06/01/2010 - "The involvement of GSK3beta in bipolar disorder: integrating evidence from multiple types of genetic studies."
02/20/2006 - "We conducted an association study to test the hypothesis that polymorphism of GSK3beta is involved in susceptibility to bipolar disorder by examining association between GSK3beta-gene polymorphisms and bipolar disorder. "
04/01/2014 - "Glycogen synthase kinase 3 beta gene structural variants as possible risk factors of bipolar depression."
|1.||glycogen synthase kinase 3 beta
|3.||NF-kappa B (NF-kB)
|5.||Glycogen Synthase (Synthase I)
|6.||4- benzyl- 2- methyl- 1,2,4- thiadiazolidine- 3,5- dione
|7.||Insulin-Like Growth Factor I (IGF-1)
|9.||Risperidone (Risperdal Consta)
|10.||Serotonin (5 Hydroxytryptamine)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)